{"id":32584,"date":"2025-04-28T13:01:51","date_gmt":"2025-04-28T05:01:51","guid":{"rendered":"https:\/\/flcube.com\/?p=32584"},"modified":"2025-04-28T13:01:52","modified_gmt":"2025-04-28T05:01:52","slug":"centrymeds-cmde005-bispecific-antibody-receives-fda-clinical-approval-for-egfr-positive-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32584","title":{"rendered":"CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors"},"content":{"rendered":"\n

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)’s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company’s proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.<\/p>\n\n\n\n

CMDE005 Mechanism and Advantages<\/strong>
CMDE005 is designed with a unique safety profile. In peripheral blood and normal tissues, the anti-CD3 end of CMDE005 remains in an inactive state. This innovative design minimizes the risk of non-specific activation and associated toxicities. Upon entering tumor tissue, tumor-specific expression proteases such as urokinase-type plasminogen activator (uPA) cleave the CMDE005-specific site. This cleavage results in the dissociation of the “shielding peptide,” releasing its binding function to CD3. Consequently, CMDE005 is converted into an active EGFR\u00d7CD3 bispecific antibody, enabling targeted anti-tumor activity while avoiding toxic side effects from non-specific killing of normal tissue. This mechanism underscores CMDE005’s high tumor-targeting capability and potential for improved safety and efficacy in treating EGFR-positive advanced solid tumors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)’s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using…<\/p>\n","protected":false},"author":1,"featured_media":32587,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4042,62,28,4041],"class_list":["post-32584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-centrymed","tag-clinical-trial-approval-initiation","tag-multi-specific-antibodies","tag-shimai-pharmaceutical"],"yoast_head":"\nCentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32584\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors\" \/>\n<meta property=\"og:description\" content=\"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32584\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T05:01:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-28T05:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors\",\"datePublished\":\"2025-04-28T05:01:51+00:00\",\"dateModified\":\"2025-04-28T05:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584\"},\"wordCount\":191,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2807.webp\",\"keywords\":[\"CentryMed\",\"Clinical trial approval \\\/ initiation\",\"Multi-specific antibodies\",\"Shimai Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32584#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32584\",\"name\":\"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2807.webp\",\"datePublished\":\"2025-04-28T05:01:51+00:00\",\"dateModified\":\"2025-04-28T05:01:52+00:00\",\"description\":\"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32584\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2807.webp\",\"width\":1080,\"height\":608,\"caption\":\"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32584#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors - Insight, China's Pharmaceutical Industry","description":"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32584","og_locale":"en_US","og_type":"article","og_title":"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors","og_description":"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=32584","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-28T05:01:51+00:00","article_modified_time":"2025-04-28T05:01:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32584#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32584"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors","datePublished":"2025-04-28T05:01:51+00:00","dateModified":"2025-04-28T05:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32584"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32584#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","keywords":["CentryMed","Clinical trial approval \/ initiation","Multi-specific antibodies","Shimai Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32584#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32584","url":"https:\/\/flcube.com\/?p=32584","name":"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32584#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32584#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","datePublished":"2025-04-28T05:01:51+00:00","dateModified":"2025-04-28T05:01:52+00:00","description":"Zhejiang-based Zhejiang Shimai Pharmaceutical Co.\uff0cLtd (CentryMed)'s CMDE005, an anti-EGFR\u00d7CD3 enzyme-controlled bispecific antibody (BsAb) developed using the company's proprietary proBiTE platform, has obtained tacit clinical approval from the US Food and Drug Administration (FDA). This approval paves the way for clinical evaluation of CMDE005 in multiple EGFR-positive advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32584#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32584"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32584#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","width":1080,"height":608,"caption":"CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32584#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32584"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32584\/revisions"}],"predecessor-version":[{"id":32588,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32584\/revisions\/32588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32587"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}